RVL Pharmaceuticals Marks a Key Milestone with Santen
RVL Pharmaceuticals, Inc. is excited to announce a significant achievement as Santen Pharmaceutical Co., Ltd., a renowned name in ophthalmology, obtains manufacturing and marketing approval in Japan for UPNEEQ Mini Ophthalmic Solution 0.1%. This innovative treatment aims to support individuals with acquired blepharoptosis, effectively addressing a condition characterized by low-lying eyelids.
Expanding Access to Non-Invasive Treatment
This groundbreaking approval in Japan signifies the introduction of the first non-invasive solution for blepharoptosis in the market, a notable enhancement from the competition, which has largely depended on surgical interventions. UPNEEQ stands as a testament to the strides made in patient care and treatment convenience. In the United States, UPNEEQ is uniquely recognized as the first FDA-approved prescription eye drop specifically designed for this condition, showcasing promising results in both patient satisfaction and a growing rate of adoption in diverse medical channels.
CEO's Insight on the Partnership
Lori Deo, the Chief Executive Officer of RVL Pharmaceuticals, expressed her enthusiasm, stating, “UPNEEQ was conceived to offer patients a feasible, non-surgical alternative to eyelid surgery. Our collaboration with Santen symbolizes our commitment to delivering this transformative solution to Japanese patients.” This partnership aims to fulfill an essential need for improved quality of life among those suffering from eyelid drooping.
Clinical Validation and Research
The approval process was fortified by a well-structured Phase 3 clinical study carried out in Japan. This study was designed as a placebo-controlled, randomized evaluation where participants received a daily dose of the product. The significant efficacy was demonstrated through measurable improvements in the primary endpoint, Marginal Reflex Distance-1 (MRD-1), just two hours post-application, and these benefits were maintained over an eight-hour period. Notably, throughout the trial, no serious adverse effects were reported, underscoring the product's safety.
The Science Behind UPNEEQ
In terms of application, MRD-1 was assessed by measuring the distance from the upper eyelid margin to the center of the pupil. The remarkable results evidenced through the clinical data validate UPNEEQ’s effectiveness and safety, prompting optimism for the future of non-invasive treatment options in ophthalmology.
Understanding UPNEEQ and Its Safety Profile
UPNEEQ, which is an oxymetazoline hydrochloride ophthalmic solution at 0.1%, is specifically formulated to alleviate acquired blepharoptosis in adult patients. Its initial approval by the FDA in the United States took place in July 2020, marking a pivotal moment in the ophthalmic therapeutic landscape.
Patients should be aware of certain safety considerations related to UPNEEQ. Conditions such as stroke, brain aneurysm, or myasthenia gravis may intersect with treatment protocols. Thus, it’s essential to inform healthcare providers of any pre-existing health issues. UPNEEQ’s administration could influence blood pressure, necessitating close monitoring for those with heart disease or blood pressure irregularities.
Additionally, care must be exercised to prevent contamination during usage. Each vial of UPNEEQ is intended for single-use only, emphasizing the importance of safe handling practices to avoid eye injury.
About RVL Pharmaceuticals and Santen
RVL Pharmaceuticals operates with a robust integrated commercial platform that stretches across product acquisition to fulfillment, ensuring that healthcare practitioners and consumers have access to essential medications. The company’s flagship product, UPNEEQ, empowers users by offering a viable, non-surgical eyelift effect with just one drop daily, delivering visible improvement in as little as five minutes.
The partnership with Santen Pharmaceuticals is reflective of RVL’s proactive strategy in eye health solutions. Santen, a firm with a rich heritage in advancing vision health since its inception in 1890, specializes in a vast array of eye care products and aims to improve patient experiences worldwide.
Frequently Asked Questions
1. What is UPNEEQ and what condition does it treat?
UPNEEQ is a prescription eye drop solution used to treat acquired blepharoptosis, or low-lying eyelids, designed as a non-invasive alternative to surgery.
2. Who developed UPNEEQ and which company is marketing it?
RVL Pharmaceuticals developed UPNEEQ, while Santen Pharmaceutical Co., Ltd. has been awarded marketing rights in Japan.
3. How has UPNEEQ been validated for safety and efficacy?
UPNEEQ’s approval was based on a Phase 3 clinical study demonstrating superior efficacy and a safe profile, with no serious adverse effects reported.
4. Can UPNEEQ be used by everyone?
Patients with certain health issues, such as heart disease or conditions affecting blood flow, should consult their healthcare provider before using UPNEEQ.
5. What is the expected duration of effect for UPNEEQ?
Once administered, UPNEEQ demonstrates its effects typically within five minutes, lasting up to eight hours.
